IP Library Granted Patent US 7,662,642
Granted Patent B2
US 7,662,642 · App. 10/681,388 · Granted Feb 16, 2010

Method for detection of specific antibodies using ubiquitin fusion proteins

Assignee: Wellstat BioCatalysis, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,642
App. No.
10/681,388
Granted
Feb 16, 2010
Kind
B2
Abstract

Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.

Claims (8)

1. A method for detecting the presence of specific antibodies in experimental or clinical samples, comprising:

a) providing a ubiquitin fusion protein selected from the group consisting of i) a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical epitopes, ii) a ubiquitin fusion protein comprising ubiquitin fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical epitopes, iii) a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical epitopes, the epitope-containing segment being fused to the ubiquitin at fusion sites selected from the group consisting of the C-terminus of the ubiquitin protein wherein said fusion site is non-cleavable, the N-terminus of the ubiquitin protein or an internal fusion site of the ubiquitin protein and, iv) a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical epitopes, the epitope-containing segment being fused to ubiquitin at the C-terminus wherein said fusion site is non-cleavable or the N-terminus of the ubiquitin protein, wherein one or more epitopes of steps (a)(i)-(a)(iv) are recognized by the antibody to be detected;

b) providing a sample suspected of comprising antibodies reactive with one or more epitopes of the ubiquitin fusion protein, said sample acquired from an experimental or clinical source;

c) forming an incubation mixture comprising the ubiquitin fusion protein of step a) and the sample of step b); and

d) detecting antibodies in the sample of step b) that bind to the epitope or epitopes of the ubiquitin fusion protein of step a) and wherein said epitopes of step a) are selected from the group consisting of HIV gp 120 V3 loop epitopes, GnRH epitopes and Growth Hormone epitopes.

2. The method of claim 1 , wherein said epitopes are HIV gp 120 V3 loop epitopes.

3. The method of claim 1 , wherein said epitopes are GnRH epitopes.

4. The method of claim 1 , wherein said epitopes are Growth Hormone epitopes.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 19, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT BIOCATALYSIS, LLC
Reel/Frame 054950/0281 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT BIOCATALYSIS, LLC
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0172 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT BIOCATALYSIS, LLC
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2009
From: PROTIENIX CORPORATION
To: WELLSTAT BIOCATALYSIS, LLC
Reel/Frame 023379/0176 →
Continuity (3)
Division 0996420100 · Sep 26, 2001
Division 0902627600 · Feb 19, 1998
Related Publication 20040170643A1 · Sep 2, 2004